University Clinic Mannheim
Welcome,         Profile    Billing    Logout  
 11 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rudic, Boris
RAVENTA, NCT03867747: Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias

Completed
N/A
20
Europe
Cardiac Radiosurgery
University Hospital Schleswig-Holstein, Universitätsmedizin Mannheim
Ventricular Tachycardia
11/23
10/24
NCT04755569: Optimizer System With ODOCOR II CCM™ Leads

Recruiting
N/A
200
Europe
ODOCOR II CCM LEADS
Impulse Dynamics
Evaluate the Safety and Useability of the ODOCOR II Intra-cardiac Lead
12/24
12/25
Dunst, Juergen
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
RAVENTA, NCT03867747: Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias

Completed
N/A
20
Europe
Cardiac Radiosurgery
University Hospital Schleswig-Holstein, Universitätsmedizin Mannheim
Ventricular Tachycardia
11/23
10/24
OLIGOMA, NCT04495309: Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer

Recruiting
N/A
564
Europe
Metastases-directed Radiotherapy
University Hospital Schleswig-Holstein
Metastatic Breast Cancer
06/23
06/25
HYPOSTAT-II, NCT03795337: Hypofractionated Radiosurgery for Localised Prostate Cancer

Active, not recruiting
N/A
475
Europe
Hypofractionated Radiosurgery
University Hospital Schleswig-Holstein, University of Luebeck, Saphir Radiosurgery Center Northern Germany
Prostate Cancer
03/24
12/25
Hofheinz, Ralf-Dieter
NCT04817189 / 2019-004686-41: Oral Akynzeo® Vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

Completed
4
414
Europe, RoW
NEPA (300mg netupitant/0.5mg palonosetron), Akynzeo® capsules, Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), 5-HT3 RA, Dexamethasone, 8 mg (oral) or equivalent IV dose, corticosteroid
Helsinn Healthcare SA
Chemotherapy-induced Nausea and Vomiting
07/24
07/24
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28
NCT04375605: Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Active, not recruiting
3
342
Europe
5-Fluorouracil, Calcium folinate, Folinic Acid, Oxaliplatin, Docetaxel, Radiation, Oxaliplatin during radiotherapy, 5-Fluorouracil during radiotherapy
Universitätsmedizin Mannheim, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Deutsche Krebshilfe e.V., Bonn (Germany)
Gastroesophageal Junction Adenocarcinoma
12/25
12/25
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
NCT04495088: Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Recruiting
3
818
Europe
mFOLFOX (neoadjuvant), Folinic acid, Oxaliplatin, 5-FU, XELOX (neoadjuvant), Capecitabine, Oxaliplatin, mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), Capecitabine, infusional 5-FU/FA "AIO" regimen (adjuvant), 5-FU, Folinic acid, infusional 5-FU/FA "de Gramont" (adjuvant)
Ralf Hofheinz, Deutsche Krebshilfe e.V., Bonn (Germany), Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, German Rectal Cancer Study Group
Rectal Cancer
08/30
08/30
OralAcu, NCT02304913: Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy

Recruiting
N/A
75
Europe
Hypoglossal acupuncture, Sham acupuncture, Dietary recommendations
Universität Duisburg-Essen
Acupuncture, Taste Disorders, Dysgeusia, Chemotherapy, Cancer
12/24
12/24
Boda-Heggemann, Judit
RAVENTA, NCT03867747: Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias

Completed
N/A
20
Europe
Cardiac Radiosurgery
University Hospital Schleswig-Holstein, Universitätsmedizin Mannheim
Ventricular Tachycardia
11/23
10/24
Bürgy, Daniel
RAVENTA, NCT03867747: Radiosurgery for the Treatment of Refractory Ventricular Extrasystoles and Tachycardias

Completed
N/A
20
Europe
Cardiac Radiosurgery
University Hospital Schleswig-Holstein, Universitätsmedizin Mannheim
Ventricular Tachycardia
11/23
10/24
Böntert, Matthias
LIPCAL-ALS II, NCT06280079: Ultra-high-caloric, Fatty Diet in ALS

Recruiting
N/A
392
Europe
Ultra-high-caloric fatty diet, Placebo
University of Ulm
Amyotrophic Lateral Sclerosis
06/27
06/27

Download Options